[{"ClinicalTrialID":1,"NCTID":"NCT02094573","ProtocolNo":"AP26113-13-201","CancerType":"Lung","Drug":"AP26113","Location":"<ul><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Pakkala, Suchita","TrialName":"A Phase 2, Multicenter, Randomized Study of AP26113"},{"ClinicalTrialID":2,"NCTID":"NCT01599754","ProtocolNo":"AP311736","CancerType":"Kidney","Drug":"Placebo, Axitinib","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Master, Viraj","TrialName":"Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients"},{"ClinicalTrialID":3,"NCTID":"NCT01787409","ProtocolNo":"LS1293","CancerType":"Non-Hodgkin's Lymphoma","Drug":"Placebo, Cholecalciferol, Calciol, Vitamin D3","Location":"Winship Cancer Institute of Emory University","Phase":"NA","Physician":"Flowers, Christopher","TrialName":"Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency"},{"ClinicalTrialID":4,"NCTID":"NCT02038946","ProtocolNo":"CA209-140","CancerType":"Non-Hodgkin's Lymphoma","Drug":"Nivolumab","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Cohen, Jonathon","TrialName":"Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)"},{"ClinicalTrialID":5,"NCTID":"NCT02011945","ProtocolNo":"CA180-373","CancerType":"Myeloid and Monocytic Leukemia","Drug":"Dasatinib, BMS-354825, Sprycel, Nivolumab","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Khoury, H. Jean","TrialName":"A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia"},{"ClinicalTrialID":6,"NCTID":"NCT01814813","ProtocolNo":"A071101","CancerType":"Brain and Nervous System","Drug":"Bevacizumab, HSPPC-96, Avastin","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Olson, Jeffrey","TrialName":"Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery"},{"ClinicalTrialID":7,"NCTID":"NCT02106546","ProtocolNo":"M11-089","CancerType":"Lung","Drug":"","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"III","Physician":"Ramalingam, Suresh","TrialName":"Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer"},{"ClinicalTrialID":8,"NCTID":"NCT00887146","ProtocolNo":"RTOG1071-13","CancerType":"Glioma, Solid Tumor Malignancies","Drug":"CCNU, procarbazine, Temozolomide, vincristine, Lomustine, Matulane, Temodal, Oncovin","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Crocker, Ian","TrialName":"Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma"},{"ClinicalTrialID":9,"NCTID":"NCT01997840","ProtocolNo":"ACE-MM-102","CancerType":"Multiple Myeloma","Drug":"Dexamethasone, ACY-1215, Pomalidomide","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Lonial, Sagar","TrialName":"ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma"},{"ClinicalTrialID":10,"NCTID":"NCT02040506","ProtocolNo":"IGN523-01","CancerType":"Myeloid and Monocytic Leukemia","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Khoury, H. Jean","TrialName":"A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML"},{"ClinicalTrialID":11,"NCTID":"NCT01896999","ProtocolNo":"E4412","CancerType":"Hodgkin's Lymphoma","Drug":"Ipilimumab, Brentuximab vedotin","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Cohen, Jonathon","TrialName":"Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma"},{"ClinicalTrialID":12,"NCTID":"NCT02038933","ProtocolNo":"CA209139","CancerType":"Hematologic Cancers, Lymphomas","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Cohen, Jonathon","TrialName":"Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)"},{"ClinicalTrialID":13,"NCTID":"NCT02257476","ProtocolNo":"WINSHIP2598-13","CancerType":"Adrenocortical, Anus, Bladder, Bones and Joints, Brain Tumors/Neurologic Cancers, Breast - Female, Breast - Male, Breast Cancer, Cervix, Clinical Trials for Multiple Types of Cancer, Colon, Colorectal, Endocrine Cancers, Esophagus, Eye and Orbit, Fallopian Tube, Gastrointestinal Cancers, Glioblastoma Multiforme, Glioma, Gynecologic Cancers, Head and Neck Cancers, Kidney (Renal), Liver, Lung Cancers, Male Cancers, Meningioma, Mesothelioma, Metastases, Neuroendocrine, Non-small Cell Lung, Ovary, Pancreas, Penis, Peritoneum, Phase 1 Clinical Trials, Prostate, Rectum, Sarcomas, Small Cell Lung, Stomach, Supportive Care Trials, Testes, Thyroid, Urologic/Genitourinary Cancers, Uterus, Vagina/Vulva","Drug":"Carfilzomib","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Carthon, Bradley","TrialName":"Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors"},{"ClinicalTrialID":14,"NCTID":"NCT02016781","ProtocolNo":"BMTCTN1102","CancerType":"Hematologic Cancers, Myelodysplastic Syndrome (MDS)","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"NA","Physician":"Arellano, Martha","TrialName":"Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)"},{"ClinicalTrialID":15,"NCTID":"NCT02017717","ProtocolNo":"CA209143","CancerType":"Brain and Nervous System","Drug":"","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"II","Physician":"Voloschin, Alfredo","TrialName":"A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143)"},{"ClinicalTrialID":16,"NCTID":"NCT01997333","ProtocolNo":"CDX011-04","CancerType":"Breast - Female","Drug":"capecitabine, Xeloda, CDX-011","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Zelnak, Amelia","TrialName":"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer"},{"ClinicalTrialID":17,"NCTID":"NCT02038647","ProtocolNo":"C14018","CancerType":"Lung","Drug":"MLN8237","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Owonikoko, Taofeek","TrialName":"Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)"},{"ClinicalTrialID":18,"NCTID":"NCT01822496","ProtocolNo":"RTOG1306","CancerType":"Lung","Drug":"carboplatin, Cisplatin, Erlotinib, Etoposide, paclitaxel, Paraplatin, CDDP, Tarceva, VP-16, Taxol, Cis-Platinum, etoposide phosphate, crizotinib","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory Saint Joseph's Hospital</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Higgins, Kristin","TrialName":"Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer"},{"ClinicalTrialID":19,"NCTID":"NCT01898494","ProtocolNo":"E3311","CancerType":"Other Respiratory and Intrathoracic Organs","Drug":"carboplatin, Cisplatin, Paraplatin, CDDP, Cis-Platinum","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Saba, Nabil","TrialName":"Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer"},{"ClinicalTrialID":20,"NCTID":"NCT02060188","ProtocolNo":"CA209142","CancerType":"Colon, Solid Tumor Malignancies","Drug":"Ipilimumab, BMS-936558, Nivolumab","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"El-Rayes, Bassel","TrialName":"A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)"},{"ClinicalTrialID":21,"NCTID":"NCT02030964","ProtocolNo":"NANT2012-01","CancerType":"Brain and Nervous System","Drug":"","Location":"<ul></ul>","Phase":"I","Physician":"Goldsmith, Kelly","TrialName":"N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan"},{"ClinicalTrialID":22,"NCTID":"NCT01535924","ProtocolNo":"OSU-11015","CancerType":"Hodgkin's Lymphoma","Drug":"Gemcitabine, Gemzar, bendamustine","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Cohen, Jonathon","TrialName":"Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma"},{"ClinicalTrialID":23,"NCTID":"NCT01606579","ProtocolNo":"PRI-724-201","CancerType":"Leukemia, other","Drug":"Dasatinib, BMS-354825, ARA-C, Sprycel, PRI-724","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Khoury, H. Jean","TrialName":"Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies"},{"ClinicalTrialID":24,"NCTID":"NCT01969838","ProtocolNo":"GS-US-352-0101","CancerType":"Hematologic Cancers, Myelofibrosis","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Winton, Elliott","TrialName":"Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis"},{"ClinicalTrialID":25,"NCTID":"NCT01923168","ProtocolNo":"CBYL719A2201","CancerType":"Breast - Female","Drug":"letrozole, Femara, BKM120, BYL719","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"II","Physician":"Zelnak, Amelia","TrialName":"Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women"},{"ClinicalTrialID":26,"NCTID":"NCT02143466","ProtocolNo":"D5160C00006","CancerType":"Lung","Drug":"AZD9291, MEDI4736, AZD6094, Selumetinib","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Ramalingam, Suresh","TrialName":"AZD9291 in Combination With Ascending Doses of Novel Therapeutics"},{"ClinicalTrialID":27,"NCTID":"NCT02255097","ProtocolNo":"MK-3475-055","CancerType":"Esophagus, Larynx","Drug":"MK-3475","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Saba, Nabil","TrialName":"Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)"},{"ClinicalTrialID":28,"NCTID":"NCT02154490","ProtocolNo":"S1400","CancerType":"Lung","Drug":"docetaxel, Erlotinib, Taxotere, Tarceva, PD-0332991, AZD4547, MEDI4736, GDC-0032, Palbociclib Isethionate, AMG 102, Rilotumumab","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Owonikoko, Taofeek","TrialName":"Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer"},{"ClinicalTrialID":29,"NCTID":"NCT01974752","ProtocolNo":"D1344C00001","CancerType":"Melanoma","Drug":"Dacarbazine, Placebo, DTIC, Selumetinib","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Kudchadkar, Ragini","TrialName":"Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)"},{"ClinicalTrialID":30,"NCTID":"NCT02181738","ProtocolNo":"CA209-205","CancerType":"Non-Hodgkin's Lymphoma","Drug":"BMS-936558, Nivolumab","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Cohen, Jonathon","TrialName":"Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205)"},{"ClinicalTrialID":31,"NCTID":"NCT02163694","ProtocolNo":"M12-914","CancerType":"Breast - Female","Drug":"carboplatin, Paraplatin, Taxol, Veliparib","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"III","Physician":"Zelnak, Amelia","TrialName":"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer"},{"ClinicalTrialID":32,"NCTID":"NCT02151981","ProtocolNo":"D5160C00003","CancerType":"Lung","Drug":"carboplatin, Cisplatin, Paraplatin, pemetrexed, CDDP, Alimta, Cis-Platinum, AZD9291","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"III","Physician":"Ramalingam, Suresh","TrialName":"AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer"},{"ClinicalTrialID":33,"NCTID":"NCT02343224","ProtocolNo":"CHOA2725-14","CancerType":"Brain and Nervous System","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Aguilera, Dolly","TrialName":"PEG-Intron for Recurrent or Refractory Juvenile Pilocytic Astrocytomas or Optic Pathway Gliomas"},{"ClinicalTrialID":34,"NCTID":"NCT02231723","ProtocolNo":"BBI608-118","CancerType":"Pancreas","Drug":"Gemcitabine, Gemzar, Nab-Paclitaxel, BBI608","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"El-Rayes, Bassel","TrialName":"A Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma"},{"ClinicalTrialID":35,"NCTID":"NCT01638546","ProtocolNo":"NCI9026","CancerType":"Lung","Drug":"Placebo, Temozolomide, Temodal, Veliparib","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Owonikoko, Taofeek","TrialName":"Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer"},{"ClinicalTrialID":36,"NCTID":"NCT02109016","ProtocolNo":"E-3810-II-02","CancerType":"Lung","Drug":"Lucitanib","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Owonikoko, Taofeek","TrialName":"A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer"},{"ClinicalTrialID":37,"NCTID":"NCT02136134","ProtocolNo":"MMY3004","CancerType":"Multiple Myeloma","Drug":"Dexamethasone, Velcade, Daratumumab","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Nooka, Ajay","TrialName":"Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma"},{"ClinicalTrialID":38,"NCTID":"NCT02187302","ProtocolNo":"CRLX101-208","CancerType":"Kidney","Drug":"Bevacizumab, Everolimus, pazopanib, sorafenib, Avastin, RAD001, GW786034, sunitinib, Axitinib, CRLX101","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Harris, Wayne","TrialName":"CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)"},{"ClinicalTrialID":39,"NCTID":"NCT01292655","ProtocolNo":"CA216001","CancerType":"Any Site","Drug":"BMS-906024","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Ramalingam, Suresh","TrialName":"Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors"},{"ClinicalTrialID":40,"NCTID":"NCT02243917","ProtocolNo":"CLC-101","CancerType":"Any Site","Drug":"CB-5083","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"El-Rayes, Bassel","TrialName":"A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors"},{"ClinicalTrialID":41,"NCTID":"NCT02359929","ProtocolNo":"EPIC2014-MSC002","CancerType":"Other Hematopoietic","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Qayed, Muna","TrialName":"BMT Auto MSCs GvHD Ph 1"},{"ClinicalTrialID":42,"NCTID":"NCT02231749","ProtocolNo":"CA209-214","CancerType":"Kidney","Drug":"sunitinib, Nivolumab","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Carthon, Bradley","TrialName":"Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)"},{"ClinicalTrialID":43,"NCTID":"NCT02101268","ProtocolNo":"GS-US-352-1214","CancerType":"Leukemia, other","Drug":"GS-0387","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Winton, Elliott","TrialName":"Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF"},{"ClinicalTrialID":44,"NCTID":"NCT02197234","ProtocolNo":"D5160C00014","CancerType":"Lung","Drug":"AZD9291, Simvastatin, CYP Substrate","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Ramalingam, Suresh","TrialName":"Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC"},{"ClinicalTrialID":45,"NCTID":"NCT02197247","ProtocolNo":"D5160C00013","CancerType":"Lung","Drug":"rifampicin","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Ramalingam, Suresh","TrialName":"Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC"},{"ClinicalTrialID":46,"NCTID":"NCT01998971","ProtocolNo":"MMY1001","CancerType":"Multiple Myeloma","Drug":"acetaminophen, Dexamethasone, diphenhydramine, Melphalan, prednisone, thalidomide, Velcade, Benadryl, Alkeran, L-PAM, Pomalidomide, Daratumumab","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Lonial, Sagar","TrialName":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma"},{"ClinicalTrialID":47,"NCTID":"NCT02186249","ProtocolNo":"CA209218-EA","CancerType":"Melanoma","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"Extended Access","Physician":"Kudchadkar, Ragini","TrialName":"Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)"},{"ClinicalTrialID":48,"NCTID":"NCT02171260","ProtocolNo":"ADVL1314","CancerType":"Any Site, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","Drug":"","Location":"<ul></ul>","Phase":"I","Physician":"Wetmore, Cynthia","TrialName":"This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas."},{"ClinicalTrialID":49,"NCTID":"NCT02130557","ProtocolNo":"AV001","CancerType":"Leukemia, other","Drug":"imatinib mesylate, Gleevac, STI 571, Bosutinib","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Kota, Vamsi","TrialName":"A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia"},{"ClinicalTrialID":50,"NCTID":"NCT01902329","ProtocolNo":"SGN33A-001","CancerType":"Myeloid and Monocytic Leukemia","Drug":"azacitidine, HMA, SGN-CD33A","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Jillella, Anand","TrialName":"A Safety Study of SGN-CD33A in AML Patients"},{"ClinicalTrialID":51,"NCTID":"NCT02204553","ProtocolNo":"CLBH589DUS94X-EA","CancerType":"Multiple Myeloma","Drug":"Bortezomib, Dexamethasone, Velcade, PS-341, Panobinostat","Location":"Winship Cancer Institute of Emory University","Phase":"Extended Access","Physician":"Kaufman, Jonathan","TrialName":"Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma"},{"ClinicalTrialID":52,"NCTID":"NCT00832338","ProtocolNo":"WCI1505-08-HRPCGREATER25","CancerType":"Breast - Female, Breast - Male, Breast Cancer","Drug":"docetaxel, Cytoxan, Taxotere","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li><li>Georgia Cancer Center for Excellence at Grady</li></ul>","Phase":"II","Physician":"Zelnak, Amelia","TrialName":"Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores"},{"ClinicalTrialID":53,"NCTID":"NCT00632853","ProtocolNo":"RTOG0538","CancerType":"Lung Cancers, Small Cell Lung","Drug":"Cisplatin, Etoposide, CDDP, VP-16, Cis-Platinum, etoposide phosphate","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"III","Physician":"Higgins, Kristin","TrialName":"Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide"},{"ClinicalTrialID":54,"NCTID":"NCT01208662","ProtocolNo":"IFM/DFCI2009","CancerType":"Hematologic Cancers, Multiple Myeloma","Drug":"Bortezomib, Dexamethasone, lenalidomide, Velcade, Revlimid, PS-341","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Lonial, Sagar","TrialName":"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65"},{"ClinicalTrialID":55,"NCTID":"NCT01498588","ProtocolNo":"WCI1937-10","CancerType":"Breast - Female, Breast - Male, Breast Cancer, Solid Tumor Malignancies","Drug":"cyclophosphamide, Doxorubicin, Cytoxan, Adriamycin, Eribulin mesylate, Halaven","Location":"<ul><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Zelnak, Amelia","TrialName":"Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer"},{"ClinicalTrialID":56,"NCTID":"NCT01220583","ProtocolNo":"RTOG1008","CancerType":"Head and Neck Cancers","Drug":"Cisplatin, CDDP, Cis-Platinum","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"II","Physician":"Beitler, Jonathan","TrialName":"Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery"},{"ClinicalTrialID":57,"NCTID":"NCT00912340","ProtocolNo":"WCI1524-08-HRMBC","CancerType":"Breast - Female, Breast - Male, Breast Cancer","Drug":"Everolimus, Trastuzumab, RAD001, Herceptin, rhuMAb HER2","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Zelnak, Amelia","TrialName":"Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer"},{"ClinicalTrialID":58,"NCTID":"NCT00590187","ProtocolNo":"CYC682-06","CancerType":"Hematologic Cancers, Leukemias, Myelodysplastic Syndrome (MDS)","Drug":"Sapacitabine","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Arellano, Martha","TrialName":"Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients"},{"ClinicalTrialID":59,"NCTID":"NCT01116336","ProtocolNo":"WCI1549-08","CancerType":"Head and Neck Cancers","Drug":"Tarceva, Green Tea Polyphenon E (PPE)","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"I","Physician":"Shin, Dong","TrialName":"Phase I Chemoprevention Trial With Green Tea Polyphenon E and Erlotinib in Patients With Premalignant Lesions of the Head and Neck"},{"ClinicalTrialID":60,"NCTID":"NCT01194869","ProtocolNo":"WCI1590-08","CancerType":"Breast - Female, Breast - Male, Breast Cancer","Drug":"Cisplatin, paclitaxel, sorafenib, CDDP, Taxol, Cis-Platinum","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Zelnak, Amelia","TrialName":"Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-) Early Stage Breast Cancer"},{"ClinicalTrialID":61,"NCTID":"NCT00626990","ProtocolNo":"RTOG0834","CancerType":"Brain Tumors/Neurologic Cancers, Glioma","Drug":"Temozolomide, Temodal","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"III","Physician":"Shu, Hui-Kuo","TrialName":"Radiation Therapy With or Without Temozolomide in Treating Patients With Anaplastic Glioma"},{"ClinicalTrialID":62,"NCTID":"NCT01218555","ProtocolNo":"WCI1717-09","CancerType":"Adrenocortical, Anus, Bladder, Bones and Joints, Brain Tumors/Neurologic Cancers, Breast - Female, Breast - Male, Breast Cancer, Cervix, Clinical Trials for Multiple Types of Cancer, Colon, Colorectal, Endocrine Cancers, Esophagus, Eye and Orbit, Fallopian Tube, Gastrointestinal Cancers, Glioblastoma Multiforme, Glioma, Gynecologic Cancers, Head and Neck Cancers, Kidney (Renal), Liver, Lung Cancers, Male Cancers, Meningioma, Mesothelioma, Non-small Cell Lung, Ovary, Pancreas, Penis, Peritoneum, Phase 1 Clinical Trials, Prostate, Rectum, Sarcomas, Small Cell Lung, Solid Tumor Malignancies, Stomach, Testes, Thyroid, Urologic/Genitourinary Cancers, Uterus, Vagina/Vulva","Drug":"Everolimus, lenalidomide, RAD001, Revlimid","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li><li>Georgia Cancer Center for Excellence at Grady</li></ul>","Phase":"I","Physician":"Owonikoko, Taofeek","TrialName":"Study of Everolimus (RAD001)in Combination With Lenalidomide"},{"ClinicalTrialID":63,"NCTID":"NCT00936390","ProtocolNo":"RTOG0815","CancerType":"Prostate, Urologic/Genitourinary Cancers","Drug":"Bicalutamide, Casodex","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Georgia Cancer Center for Excellence at Grady</li></ul>","Phase":"III","Physician":"Jani, Ashesh","TrialName":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer"},{"ClinicalTrialID":64,"NCTID":"NCT00700882","ProtocolNo":"E2607","CancerType":"Melanoma","Drug":"Dasatinib, BMS-354825, Sprycel","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Lawson, David","TrialName":"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery"},{"ClinicalTrialID":65,"NCTID":"NCT01188109","ProtocolNo":"WCI1738-09","CancerType":"Gastrointestinal Cancers, Pancreas","Drug":"","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Maithel, Shishir","TrialName":"Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision"},{"ClinicalTrialID":66,"NCTID":"NCT00956007","ProtocolNo":"RTOG0920","CancerType":"Head and Neck Cancers","Drug":"Cetuximab, Erbitux, C225","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"III","Physician":"Beitler, Jonathan","TrialName":"Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer"},{"ClinicalTrialID":67,"NCTID":"NCT01270321","ProtocolNo":"WCI1777-09","CancerType":"Endocrine Cancers, Thyroid","Drug":"Everolimus, RAD001, Pasireotide","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Owonikoko, Taofeek","TrialName":"A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer"},{"ClinicalTrialID":68,"NCTID":"NCT01218542","ProtocolNo":"WCI1784-10","CancerType":"Adrenocortical, Anus, Bladder, Brain Tumors/Neurologic Cancers, Breast - Female, Breast - Male, Breast Cancer, Cervix, Clinical Trials for Multiple Types of Cancer, Colon, Colorectal, Endocrine Cancers, Eye and Orbit, Fallopian Tube, Gastrointestinal Cancers, Gynecologic Cancers, Head and Neck Cancers, Kidney (Renal), Liver, Lung Cancers, Male Cancers, Mesothelioma, Metastases, Non-small Cell Lung, Ovary, Pancreas, Penis, Peritoneum, Phase 1 Clinical Trials, Prostate, Rectum, Solid Tumor Malignancies, Spine, Stomach, Testes, Thyroid, Urologic/Genitourinary Cancers, Uterus, Vagina/Vulva","Drug":"","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"I","Physician":"Shu, Hui-Kuo","TrialName":"Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc"},{"ClinicalTrialID":69,"NCTID":"NCT01055197","ProtocolNo":"RTOG0937","CancerType":"Lung Cancers, Small Cell Lung","Drug":"","Location":"<ul><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Higgins, Kristin","TrialName":"Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer"},{"ClinicalTrialID":70,"NCTID":"NCT01435395","ProtocolNo":"WCI1837-10","CancerType":"Brain Tumors/Neurologic Cancers, Solid Tumor Malignancies","Drug":"Bevacizumab, Bortezomib, Temozolomide, Avastin, Velcade, Temodal, PS-341","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"I","Physician":"Olson, Jeffrey","TrialName":"Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme"},{"ClinicalTrialID":71,"NCTID":"","ProtocolNo":"WCI1869-10","CancerType":"Breast - Female, Breast Cancer, Solid Tumor Malignancies","Drug":"","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"Pilot","Physician":"Torres, Mylin","TrialName":"WCI1869-10: A Pilot Study of Hypofractionated Simultaneous Integrated Boost Radiotherapy in Stage 0, I and II Breast Cancer Patients"},{"ClinicalTrialID":72,"NCTID":"NCT01490749","ProtocolNo":"WCI1871-10-CRAD001CUS159T","CancerType":"Esophagus, Solid Tumor Malignancies","Drug":"capecitabine, carboplatin, oxaliplatin, Paraplatin, Xeloda, RAD001","Location":"<ul><li>Vanderbilt-Ingram Cancer Center</li><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"I","Physician":"Saba, Nabil","TrialName":"Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer"},{"ClinicalTrialID":73,"NCTID":"NCT01107626","ProtocolNo":"E5508","CancerType":"Lung Cancers, Non-small Cell Lung, Solid Tumor Malignancies","Drug":"Bevacizumab, carboplatin, paclitaxel, Paraplatin, pemetrexed, Avastin, Taxol, Alimta","Location":"<ul><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory Saint Joseph's Hospital</li></ul>","Phase":"III","Physician":"Ramalingam, Suresh","TrialName":"Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer"},{"ClinicalTrialID":74,"NCTID":"NCT01470209","ProtocolNo":"WCI1925-10","CancerType":"Adrenocortical, Anus, Bladder, Bones and Joints, Brain Tumors/Neurologic Cancers, Breast - Female, Breast - Male, Breast Cancer, Cervix, Clinical Trials for Multiple Types of Cancer, Colon, Colorectal, Endocrine Cancers, Esophagus, Eye and Orbit, Fallopian Tube, Gastrointestinal Cancers, Glioblastoma Multiforme, Glioma, Gynecologic Cancers, Head and Neck Cancers, Kidney (Renal), Liver, Lung Cancers, Male Cancers, Meningioma, Mesothelioma, Metastases, Non-small Cell Lung, Ovary, Pancreas, Penis, Peritoneum, Phase 1 Clinical Trials, Prostate, Rectum, Sarcomas, Small Cell Lung, Solid Tumor Malignancies, Stomach, Testes, Thyroid, Urologic/Genitourinary Cancers, Uterus, Vagina/Vulva","Drug":"Everolimus, RAD001, BKM120","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"I","Physician":"Owonikoko, Taofeek","TrialName":"A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies"},{"ClinicalTrialID":75,"NCTID":"NCT00859781","ProtocolNo":"0810010067","CancerType":"Prostate","Drug":"hydrocortisone, ketoconazole, 177Lu-J591, 111In-J591","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Kucuk, Omer","TrialName":"177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer"},{"ClinicalTrialID":76,"NCTID":"NCT00567580","ProtocolNo":"RTOG0534","CancerType":"Prostate, Urologic/Genitourinary Cancers","Drug":"","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship at Emory Saint Joseph's Hospital</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"III","Physician":"Rossi, Peter","TrialName":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer"},{"ClinicalTrialID":77,"NCTID":"NCT02193282","ProtocolNo":"A081105","CancerType":"Lung","Drug":"Erlotinib, Placebo, Tarceva","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"III","Physician":"Owonikoko, Taofeek","TrialName":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)"},{"ClinicalTrialID":78,"NCTID":"NCT02279719","ProtocolNo":"BBIHCC-103","CancerType":"Liver","Drug":"sorafenib, BBI608, BBI503","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"El-Rayes, Bassel","TrialName":"A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma"},{"ClinicalTrialID":79,"NCTID":"NCT02296125","ProtocolNo":"D5160C00007","CancerType":"Lung","Drug":"Erlotinib, Gefitinib, Placebo, Tarceva, IRESSA, ZD1839, AZD9291","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"III","Physician":"Ramalingam, Suresh","TrialName":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer"},{"ClinicalTrialID":80,"NCTID":"NCT02302807","ProtocolNo":"GO29294","CancerType":"Bladder","Drug":"MPDL3280A","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Carthon, Bradley","TrialName":"A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer"},{"ClinicalTrialID":81,"NCTID":"NCT02006485","ProtocolNo":"UTX-TGR-103","CancerType":"Lymphoid Leukemia, Non-Hodgkin's Lymphoma","Drug":"Ibrutinib, Ublituximab, TGR-1202","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Flowers, Christopher","TrialName":"Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies"},{"ClinicalTrialID":82,"NCTID":"NCT01824875","ProtocolNo":"E2211","CancerType":"Pancreas","Drug":"capecitabine, Temozolomide, Xeloda, Temodal","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Shaib, Walid","TrialName":"Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors"},{"ClinicalTrialID":83,"NCTID":"NCT02286492","ProtocolNo":"TO-TAS-102-401-EA","CancerType":"Colon, Rectum","Drug":"TAS-102","Location":"Winship Cancer Institute of Emory University","Phase":"Extended Access","Physician":"El-Rayes, Bassel","TrialName":"Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer"},{"ClinicalTrialID":84,"NCTID":"NCT02065687","ProtocolNo":"GOG-0286B","CancerType":"Corpus Uteri","Drug":"carboplatin, paclitaxel, Paraplatin, Taxol","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"II","Physician":"Khanna, Namita","TrialName":"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer"},{"ClinicalTrialID":85,"NCTID":"NCT02273960","ProtocolNo":"IM140-103","CancerType":"Other","Drug":"BMS-986004","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Antun, Ana","TrialName":"Study to Evaluate Safety and Efficacy in Adult Subjects With ITP"},{"ClinicalTrialID":86,"NCTID":"NCT02254278","ProtocolNo":"NRG-HN002","CancerType":"Lip, Oral Cavity and Pharynx","Drug":"Cisplatin, CDDP, Cis-Platinum","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Beitler, Jonathan","TrialName":"Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer"},{"ClinicalTrialID":87,"NCTID":"NCT02200042","ProtocolNo":"NRG-GI001","CancerType":"Liver","Drug":"Cisplatin, Gemcitabine, CDDP, Gemzar, Cis-Platinum","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"III","Physician":"Vainshtein, Jeffrey","TrialName":"Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed By Surgery"},{"ClinicalTrialID":88,"NCTID":"NCT02206334","ProtocolNo":"NRG-BR001","CancerType":"Breast - Female, Breast - Male, Lung, Prostate","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Patel, Pretesh","TrialName":"Stereotactic Radiosurgery in Treating Patients With Metastatic Breast Cancer, Non-Small Cell Lung Cancer, or Prostate Cancer"},{"ClinicalTrialID":89,"NCTID":"NCT01013649","ProtocolNo":"RTOG0848","CancerType":"Pancreas","Drug":"5-fluorouracil, capecitabine, Erlotinib, Gemcitabine, 5-FU, Xeloda, Tarceva, Gemzar, Adrucil","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory Saint Joseph's Hospital</li></ul>","Phase":"II","Physician":"El-Rayes, Bassel","TrialName":"Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery"},{"ClinicalTrialID":90,"NCTID":"NCT02201992","ProtocolNo":"E4512","CancerType":"Lung","Drug":"Placebo, crizotinib","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"III","Physician":"Owonikoko, Taofeek","TrialName":"Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)"},{"ClinicalTrialID":91,"NCTID":"NCT02273752","ProtocolNo":"WINSHIP2645-14","CancerType":"Breast - Female, Kidney","Drug":"Everolimus, RAD001","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Harvey, R. Donald","TrialName":"Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer"},{"ClinicalTrialID":92,"NCTID":"NCT01253707","ProtocolNo":"AMG337","CancerType":"Any Site","Drug":"AMG 337","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Ramalingam, Suresh","TrialName":"A Study of AMG 337 in Subjects With Advanced Solid Tumors"},{"ClinicalTrialID":93,"NCTID":"NCT02223598","ProtocolNo":"CLC-102","CancerType":"Multiple Myeloma","Drug":"Dexamethasone, CB-5083","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Nooka, Ajay","TrialName":"A Phase 1 Study Evaluating CB-5083 in Patients With Relapsed/Refractory Multiple Myeloma"},{"ClinicalTrialID":94,"NCTID":"NCT01886872","ProtocolNo":"A041202","CancerType":"Lymphoid Leukemia","Drug":"Rituximab, Rituxan, bendamustine, Ibrutinib","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Heffner, L. Thompson","TrialName":"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia"},{"ClinicalTrialID":95,"NCTID":"NCT02120417","ProtocolNo":"INCB18424-268","CancerType":"Breast - Female, Breast - Male","Drug":"capecitabine, Xeloda, Ruxolitinib","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Zelnak, Amelia","TrialName":"A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer"},{"ClinicalTrialID":96,"NCTID":"NCT02017964","ProtocolNo":"ACNS1221","CancerType":"Brain and Nervous System","Drug":"carboplatin, cyclophosphamide, Etoposide, methotrexate, Paraplatin, Cytoxan, VP-16, MTX, etoposide phosphate, Vincristine Sulfate","Location":"<ul></ul>","Phase":"II","Physician":"MacDonald, Tobey","TrialName":"Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma"},{"ClinicalTrialID":97,"NCTID":"NCT02105636","ProtocolNo":"CA209-141","CancerType":"Esophagus, Larynx, Lip, Oral Cavity and Pharynx","Drug":"Cetuximab, docetaxel, methotrexate, Erbitux, Taxotere, MTX, C225, Nivolumab","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"III","Physician":"Saba, Nabil","TrialName":"Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)"},{"ClinicalTrialID":98,"NCTID":"NCT02039726","ProtocolNo":"AC220-007","CancerType":"Myeloid and Monocytic Leukemia","Drug":"Etoposide, Idarubicin, mitoxantrone, Cytarabine, VP-16, Zevados, Novantrone, etoposide phosphate, G-CSF, Quizartinib, AC220","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Arellano, Martha","TrialName":"An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects"},{"ClinicalTrialID":99,"NCTID":"NCT02244112","ProtocolNo":"OPZ009","CancerType":"Multiple Myeloma","Drug":"Oprozomib","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Harvey, R. Donald","TrialName":"A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies"},{"ClinicalTrialID":100,"NCTID":"NCT02071862","ProtocolNo":"CX-839-001","CancerType":"Any Site","Drug":"CB-839","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Owonikoko, Taofeek","TrialName":"Study of the Glutaminase Inhibitor CB-839 in Solid Tumors"},{"ClinicalTrialID":101,"NCTID":"NCT02122770","ProtocolNo":"C15011","CancerType":"Any Site","Drug":"carboplatin, docetaxel, fluconazole, Itraconazole, paclitaxel, Paraplatin, Taxotere, Diflucan, Itronazole, Taxol, MLN4924","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Harvey, R. Donald","TrialName":"Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors"},{"ClinicalTrialID":102,"NCTID":"NCT02076009","ProtocolNo":"MMY3003","CancerType":"Multiple Myeloma","Drug":"Dexamethasone, lenalidomide, Revlimid, Daratumumab","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Kaufman, Jonathan","TrialName":"A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma"},{"ClinicalTrialID":103,"NCTID":"NCT02034552","ProtocolNo":"BAY88-8223","CancerType":"Prostate","Drug":"prednisone, Abiraterone, Enzalutamide, Radium-223 dichloride (Xofigo,BAY88-8223)","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Kucuk, Omer","TrialName":"A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)"},{"ClinicalTrialID":104,"NCTID":"NCT02071888","ProtocolNo":"CX-839-002","CancerType":"Leukemia, other, Lymphoid Leukemia, Multiple Myeloma, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma","Drug":"CB-839","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Kaufman, Jonathan","TrialName":"Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors"},{"ClinicalTrialID":105,"NCTID":"NCT02158936","ProtocolNo":"GSKTRC112121","CancerType":"Leukemia, other","Drug":"azacitidine, Placebo, Eltrombopag olamine, Promacta, SB-497115, SB 497115, SB497115","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Arellano, Martha","TrialName":"A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)"},{"ClinicalTrialID":106,"NCTID":"NCT01979523","ProtocolNo":"NCI9445","CancerType":"Melanoma","Drug":"Trametinib, Oral Akt Inhibitor GSK2141795","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Kudchadkar, Ragini","TrialName":"Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma"},{"ClinicalTrialID":107,"NCTID":"NCT02208037","ProtocolNo":"BMTCTN1203","CancerType":"Leukemia, not otherwise specified, Leukemia, other, Lymphoid Leukemia, Other Hematopoietic","Drug":"Bortezomib, cyclophosphamide, methotrexate, mycophenolate mofetil, prograf, tacrolimus, Velcade, Cytoxan, MTX, Cellcept, PS-341, Maraviroc; (Brand Name: Selzentry®)","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Al-Kadhimi, Zaid","TrialName":"Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)"},{"ClinicalTrialID":108,"NCTID":"NCT02117219","ProtocolNo":"D4190C00007","CancerType":"Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia, Other Hematopoietic","Drug":"MEDI4736","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Gaddh, Manila","TrialName":"Phase 1 Study to Evaluate MEDI4736"},{"ClinicalTrialID":109,"NCTID":"NCT02039947","ProtocolNo":"BRF117277","CancerType":"Melanoma","Drug":"Dabrafenib, Trametinib","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Kudchadkar, Ragini","TrialName":"Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain"},{"ClinicalTrialID":110,"NCTID":"NCT02092922","ProtocolNo":"ARRAY-520-215","CancerType":"Multiple Myeloma","Drug":"G-CSF, ARRY-520, Filanesib","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Lonial, Sagar","TrialName":"A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)"},{"ClinicalTrialID":111,"NCTID":"NCT02115282","ProtocolNo":"E2112","CancerType":"Breast - Female, Breast - Male","Drug":"exemestane, Placebo, Aromasin, Entinostat, Gosereline acetate","Location":"<ul><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"III","Physician":"O'Regan, Ruth","TrialName":"Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That Is Locally Advanced or Metastatic"},{"ClinicalTrialID":112,"NCTID":"NCT02165397","ProtocolNo":"PCYC-1127-CA","CancerType":"Multiple Myeloma","Drug":"Placebo, Rituximab, Rituxan, Ibrutinib","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Heffner, L. Thompson","TrialName":"Ibrutinib With Rituximab in Previously Treated Adults With Waldenstrom's Macroglobulinemia"},{"ClinicalTrialID":113,"NCTID":"","ProtocolNo":"WINSHIP-00074410-2688-14","CancerType":"Breast - Female","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"Pilot","Physician":"Gillespie, Theresa","TrialName":"Winship-00074410-2688-14: Pilot Study of an Intervention to Enhance Risk Comprehension and Informed Decision Making in Women with DCIS or at Increased Risk for Breast Cancer"},{"ClinicalTrialID":114,"NCTID":"NCT02048813","ProtocolNo":"E1912","CancerType":"Lymphoid Leukemia","Drug":"cyclophosphamide, Rituximab, Cytoxan, Rituxan, fludarabine phosphate, Ibrutinib","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Heffner, L. Thompson","TrialName":"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"},{"ClinicalTrialID":115,"NCTID":"NCT01950390","ProtocolNo":"E3612","CancerType":"Melanoma, Solid Tumor Malignancies","Drug":"Bevacizumab, Avastin, Ipilimumab","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Lawson, David","TrialName":"Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery"},{"ClinicalTrialID":116,"NCTID":"NCT01336920","ProtocolNo":"UNMC518-10","CancerType":"Non-Hodgkin's Lymphoma","Drug":"Carfilzomib","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Lechowicz, Mary Jo","TrialName":"Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma"},{"ClinicalTrialID":117,"NCTID":"NCT01836029","ProtocolNo":"VRXP-A202","CancerType":"Head and Neck Cancers, Solid Tumor Malignancies","Drug":"5-fluorouracil, carboplatin, Cetuximab, Cisplatin, Paraplatin, Placebo, 5-FU, Erbitux, CDDP, Adrucil, C225, Cis-Platinum, VTX-2337","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Saba, Nabil","TrialName":"Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck"},{"ClinicalTrialID":118,"NCTID":"NCT01446458","ProtocolNo":"WCI1998-11","CancerType":"Pancreas, Solid Tumor Malignancies","Drug":"5-fluorouracil, irinotecan, oxaliplatin, pegfilgrastim, 5-FU, Leucovorin, Camptosar, Neulasta, Adrucil, CPT-11, Folfirinox","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"I","Physician":"Hawk, Natalyn","TrialName":"Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer"},{"ClinicalTrialID":119,"NCTID":"NCT01445691","ProtocolNo":"WCI1999-11","CancerType":"Brain Tumors/Neurologic Cancers, Solid Tumor Malignancies","Drug":"5-Aminolevulinic Acid (ALA)","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>University of Michigan</li><li>Winship at Emory Saint Joseph's Hospital</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"II","Physician":"Hadjipanayis, Costas","TrialName":"More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery"},{"ClinicalTrialID":120,"NCTID":"NCT01079780","ProtocolNo":"E7208","CancerType":"Colon, Gastrointestinal Cancers, Solid Tumor Malignancies","Drug":"Cetuximab, irinotecan, Erbitux, Camptosar, C225, CPT-11, Ramucirumab","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Hawk, Natalyn","TrialName":"Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy"},{"ClinicalTrialID":121,"NCTID":"NCT01711658","ProtocolNo":"RTOGFOUNDATION3501","CancerType":"Head and Neck Cancers, Solid Tumor Malignancies","Drug":"Cisplatin, lapatinib, Placebo, CDDP, Cis-Platinum","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Beitler, Jonathan","TrialName":"TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer."},{"ClinicalTrialID":122,"NCTID":"NCT01769170","ProtocolNo":"CMX001-301","CancerType":"Hematologic Cancers","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Langston, Amelia","TrialName":"A Study of the Safety and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients"},{"ClinicalTrialID":123,"NCTID":"NCT01951690","ProtocolNo":"VS-6063-201","CancerType":"Lung Cancers, Non-small Cell Lung, Solid Tumor Malignancies","Drug":"","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Ramalingam, Suresh","TrialName":"Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer"},{"ClinicalTrialID":124,"NCTID":"NCT01485835","ProtocolNo":"WCI2005-11/MMRC037","CancerType":"Hematologic Cancers, Multiple Myeloma","Drug":"Bortezomib, Dexamethasone, Gemcitabine, Velcade, Gemzar, PS-341, Ganetespib","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"I","Physician":"Lonial, Sagar","TrialName":"A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma"},{"ClinicalTrialID":125,"NCTID":"NCT01594229","ProtocolNo":"M12-630","CancerType":"Hematologic Cancers, Lymphomas","Drug":"Rituximab, Rituxan, bendamustine, ABT-199","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Flowers, Christopher","TrialName":"A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma"},{"ClinicalTrialID":126,"NCTID":"NCT01576406","ProtocolNo":"A8081012","CancerType":"Adrenocortical, Anus, Bladder, Bones and Joints, Brain Tumors/Neurologic Cancers, Breast - Female, Breast - Male, Breast Cancer, Cervix, Clinical Trials for Multiple Types of Cancer, Colon, Colorectal, Endocrine Cancers, Esophagus, Eye and Orbit, Fallopian Tube, Gastrointestinal Cancers, Glioblastoma Multiforme, Glioma, Gynecologic Cancers, Head and Neck Cancers, Hematologic Cancers, Kidney (Renal), Liver, Lung Cancers, Lymphomas, Male Cancers, Mantle Cell Lymphoma, Meningioma, Mesothelioma, Metastases, Non-small Cell Lung, Ovary, Pancreas, Penis, Peritoneum, Phase 1 Clinical Trials, Prostate, Rectum, Sarcomas, Small Cell Lung, Solid Tumor Malignancies, Stomach, Testes, Thyroid, Urologic/Genitourinary Cancers, Uterus, Vagina/Vulva","Drug":"crizotinib","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"El-Rayes, Bassel","TrialName":"Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients"},{"ClinicalTrialID":127,"NCTID":"NCT01730950","ProtocolNo":"RTOG1205","CancerType":"Brain Tumors/Neurologic Cancers, Solid Tumor Malignancies","Drug":"Bevacizumab, Avastin","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Crocker, Ian","TrialName":"Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma"},{"ClinicalTrialID":128,"NCTID":"NCT01790295","ProtocolNo":"MPD-RC114","CancerType":"Myelofibrosis","Drug":"Ruxolitinib","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Langston, Amelia","TrialName":"Ruxolitinib Prior to Transplant in Patients With Myelofibrosis"},{"ClinicalTrialID":129,"NCTID":"NCT01549431","ProtocolNo":"WCI2011-11MMRC036","CancerType":"Hematologic Cancers, Multiple Myeloma","Drug":"Carfilzomib, Panobinostat","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"I","Physician":"Kaufman, Jonathan","TrialName":"A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma"},{"ClinicalTrialID":130,"NCTID":"NCT01079780","ProtocolNo":"E7208-VA","CancerType":"Colon","Drug":"Cetuximab, irinotecan, Erbitux, Camptosar, C225, CPT-11, Ramucirumab","Location":"<ul></ul>","Phase":"II","Physician":"Chan, Samuel","TrialName":"Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy"},{"ClinicalTrialID":131,"NCTID":"NCT01743131","ProtocolNo":"GVH1201","CancerType":"GVHD (Graft vs. Host Disease), Hematologic Cancers","Drug":"methotrexate, Placebo, MTX, Abatacept","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Langston, Amelia","TrialName":"Abatacept as GVHD Prophylaxis Phase 2"},{"ClinicalTrialID":132,"NCTID":"NCT01696461","ProtocolNo":"09-PLEX","CancerType":"Hematologic Cancers","Drug":"Plerixafor, Mozobil","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Waller, Edmund","TrialName":"A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor"},{"ClinicalTrialID":133,"NCTID":"NCT01575925","ProtocolNo":"CC-4047-MM-008","CancerType":"Multiple Myeloma","Drug":"Dexamethasone, Pomalidomide","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Lonial, Sagar","TrialName":"Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiply Myeloma and Impaired Renal Function (POM Renal)"},{"ClinicalTrialID":134,"NCTID":"NCT01928394","ProtocolNo":"CA209032","CancerType":"Adrenocortical, Anus, Bladder, Bones and Joints, Brain Tumors/Neurologic Cancers, Breast - Female, Breast - Male, Breast Cancer, Cervix, Clinical Trials for Multiple Types of Cancer, Colon, Colorectal, Endocrine Cancers, Esophagus, Eye and Orbit, Fallopian Tube, Gastrointestinal Cancers, Glioblastoma Multiforme, Glioma, Gynecologic Cancers, Head and Neck Cancers, Kidney (Renal), Liver, Lung Cancers, Male Cancers, Meningioma, Mesothelioma, Metastases, Neuroendocrine, Non-small Cell Lung, Ovary, Pancreas, Penis, Peritoneum, Phase 1 Clinical Trials, Prostate, Rectum, Sarcomas, Small Cell Lung, Stomach, Supportive Care Trials, Testes, Thyroid, Urologic/Genitourinary Cancers, Uterus, Vagina/Vulva","Drug":"Ipilimumab, BMS-936558, Nivolumab","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"I","Physician":"Pillai, Rathi","TrialName":"A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors"},{"ClinicalTrialID":135,"NCTID":"NCT01273155","ProtocolNo":"NCI8846","CancerType":"Male Cancers, Meningioma, Mesothelioma, Metastases, Non-small Cell Lung, Ovary, Pancreas, Penis, Peritoneum, Phase 1 Clinical Trials, Prostate, Rectum, Sarcomas, Small Cell Lung, Solid Tumor Malignancies, Stomach, Testes, Thyroid, Urologic/Genitourinary Cancers, Uterus, Vagina/Vulva, Adrenocortical, Anus, Bladder, Bones and Joints, Brain Tumors/Neurologic Cancers, Breast - Female, Breast - Male, Breast Cancer, Cervix, Clinical Trials for Multiple Types of Cancer, Colon, Colorectal, Endocrine Cancers, Esophagus, Eye and Orbit, Fallopian Tube, Gastrointestinal Cancers, Glioblastoma Multiforme, Glioma, Gynecologic Cancers, Head and Neck Cancers, Hematologic Cancers, Kidney (Renal), Leukemias, Liver, Lung Cancers, Lymphomas","Drug":"Belinostat","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"El-Rayes, Bassel","TrialName":"Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction"},{"ClinicalTrialID":136,"NCTID":"NCT01348490","ProtocolNo":"INCB18424-258","CancerType":"Hematologic Cancers, Leukemias","Drug":"Ruxolitinib","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Winton, Elliott","TrialName":"Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis"},{"ClinicalTrialID":137,"NCTID":"NCT01666808","ProtocolNo":"CA16918801","CancerType":"Gastrointestinal Cancers, Solid Tumor Malignancies","Drug":"","Location":"<ul><li>Winship at Emory Saint Joseph's Hospital</li><li>Winship at Emory University Hospital Midtown</li><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"II","Physician":"Jani, Ashesh","TrialName":"FACBC Outcomes for Post Prostatectomy"},{"ClinicalTrialID":138,"NCTID":"NCT01414608","ProtocolNo":"RTOG1174","CancerType":"Gynecologic Cancers, Solid Tumor Malignancies","Drug":"carboplatin, Cisplatin, paclitaxel, Paraplatin, CDDP, Taxol, Cis-Platinum","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"III","Physician":"Shelton, Joseph (Jay)","TrialName":"Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer"},{"ClinicalTrialID":139,"NCTID":"NCT01602315","ProtocolNo":"CBYL719X2104","CancerType":"Head and Neck Cancers, Solid Tumor Malignancies","Drug":"Cetuximab, Erbitux, C225, BYL719","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Saba, Nabil","TrialName":"A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma"},{"ClinicalTrialID":140,"NCTID":"NCT01575548","ProtocolNo":"E2810","CancerType":"Kidney (Renal), Solid Tumor Malignancies","Drug":"pazopanib, Placebo, GW786034","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory Saint Joseph's Hospital</li></ul>","Phase":"III","Physician":"Harris, Wayne","TrialName":"Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery"},{"ClinicalTrialID":141,"NCTID":"NCT01672892","ProtocolNo":"RTOG1203","CancerType":"Cervix","Drug":"","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li><li>Georgia Cancer Center for Excellence at Grady</li></ul>","Phase":"III","Physician":"Shelton, Joseph (Jay)","TrialName":"Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer"},{"ClinicalTrialID":142,"NCTID":"NCT01164228","ProtocolNo":"E1808","CancerType":"Kidney","Drug":"Gemcitabine, Gemzar, sunitinib","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Harris, Wayne","TrialName":"Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery"},{"ClinicalTrialID":143,"NCTID":"NCT01597778","ProtocolNo":"BMTCTN1101","CancerType":"Hematologic Cancers, Leukemias, Lymphomas","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Langston, Amelia","TrialName":"Double Cord Versus Haploidentical (BMT CTN 1101)"},{"ClinicalTrialID":144,"NCTID":"NCT02075112","ProtocolNo":"RAD2412-13","CancerType":"Head and Neck Cancers, Solid Tumor Malignancies","Drug":"Cisplatin, CDDP, Cis-Platinum, Soy Isoflavone, Genistein","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"Pilot","Physician":"Higgins, Kristin","TrialName":"Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck"},{"ClinicalTrialID":145,"NCTID":"NCT01798485","ProtocolNo":"9090-14","CancerType":"Lung Cancers, Non-small Cell Lung, Solid Tumor Malignancies","Drug":"docetaxel, Taxotere, Ganetespib","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"III","Physician":"Ramalingam, Suresh","TrialName":"A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC"},{"ClinicalTrialID":146,"NCTID":"NCT01824823","ProtocolNo":"E1311","CancerType":"Head and Neck Cancers, Solid Tumor Malignancies","Drug":"","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"II","Physician":"Saba, Nabil","TrialName":"Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence"},{"ClinicalTrialID":147,"NCTID":"NCT01084252","ProtocolNo":"TED10893","CancerType":"Hematologic Cancers, Leukemias, Lymphomas, Mantle Cell Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome (MDS), Myelofibrosis, Phase 1 Clinical Trials, Waldenstrom's Macroglobulinemia","Drug":"SAR650984","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Kaufman, Jonathan","TrialName":"Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies"},{"ClinicalTrialID":148,"NCTID":"NCT01326871","ProtocolNo":"CA-ALT-801-01-10","CancerType":"Bladder, Kidney (Renal), Solid Tumor Malignancies, Urologic/Genitourinary Cancers","Drug":"Cisplatin, Gemcitabine, CDDP, Gemzar, Cis-Platinum, ALT-801","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Harris, Wayne","TrialName":"A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer"},{"ClinicalTrialID":149,"NCTID":"NCT01659645","ProtocolNo":"RAD2083-11","CancerType":"Breast - Female, Breast Cancer, Solid Tumor Malignancies","Drug":"F-FACBC","Location":"Winship Cancer Institute of Emory University","Phase":"Pilot","Physician":"Schuster, David","TrialName":"Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast"},{"ClinicalTrialID":150,"NCTID":"NCT01954173","ProtocolNo":"RAD2271-12","CancerType":"Bladder, Solid Tumor Malignancies","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Shelton, Joseph (Jay)","TrialName":"Radiation Therapy After Surgery in Treating Patients With High-Risk Bladder Cancer"},{"ClinicalTrialID":151,"NCTID":"","ProtocolNo":"RAD2278-12","CancerType":"Liver","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"Pilot","Physician":"Schuster, David","TrialName":"RAD2278-12: The Inflammatory Response After Single Hepatic Neoplastic Lesion RFA on Adjacent hepatic Malignant Lesions"},{"ClinicalTrialID":152,"NCTID":"NCT01758588","ProtocolNo":"1202012178","CancerType":"Hematologic Cancers, Myelofibrosis","Drug":"PEG-IFN alpha 2a, Pegasys","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Winton, Elliott","TrialName":"Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis"},{"ClinicalTrialID":153,"NCTID":"NCT01933269","ProtocolNo":"RAD2424-13","CancerType":"Esophagus, Lip, Oral Cavity and Pharynx, Other Respiratory and Intrathoracic Organs","Drug":"","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"Pilot","Physician":"Kendi, Ayse","TrialName":"FACBC for Head and Neck Cancers"},{"ClinicalTrialID":154,"NCTID":"NCT01810913","ProtocolNo":"RTOG1216","CancerType":"Head and Neck Cancers, Lung Cancers, Solid Tumor Malignancies","Drug":"Cetuximab, Cisplatin, docetaxel, Erbitux, CDDP, Taxotere, C225, Cis-Platinum","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Beitler, Jonathan","TrialName":"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer"},{"ClinicalTrialID":155,"NCTID":"NCT01368588","ProtocolNo":"RTOG0924","CancerType":"Prostate, Solid Tumor Malignancies","Drug":"","Location":"<ul><li>Winship at Emory Saint Joseph's Hospital</li><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"III","Physician":"Jani, Ashesh","TrialName":"Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer"},{"ClinicalTrialID":156,"NCTID":"NCT01794520","ProtocolNo":"M13-367","CancerType":"Hematologic Cancers, Multiple Myeloma","Drug":"ABT-199","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Kaufman, Jonathan","TrialName":"Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma"},{"ClinicalTrialID":157,"NCTID":"NCT01366144","ProtocolNo":"NCI8808","CancerType":"Clinical Trials for Multiple Types of Cancer, Kidney (Renal), Male Cancers, Phase 1 Clinical Trials, Solid Tumor Malignancies","Drug":"carboplatin, paclitaxel, Paraplatin, Taxol, ABT-888, Veliparib","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Ramalingam, Suresh","TrialName":"Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction"},{"ClinicalTrialID":158,"NCTID":"NCT02074436","ProtocolNo":"WINSHIP2429-13","CancerType":"Hematologic Cancers, Leukemias, Lymphomas, Mantle Cell Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome (MDS), Myelofibrosis","Drug":"Epsilon Aminocaproic Acid (EACA)","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Antun, Ana","TrialName":"PRevention Of BLeeding in hEmatological Malignancies w/ Antifibrinolytic Agents"},{"ClinicalTrialID":159,"NCTID":"NCT01890746","ProtocolNo":"TRC117146","CancerType":"Myeloid and Monocytic Leukemia","Drug":"Placebo, Cytarabine, Daunorubicin","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Antun, Ana","TrialName":"A Safety and Efficacy Study of Eltrombopag in Subjects With AML"},{"ClinicalTrialID":160,"NCTID":"NCT01554969","ProtocolNo":"WCI2108-11","CancerType":"Rectum, Solid Tumor Malignancies","Drug":"capecitabine, Xeloda, Ganetespib","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory Saint Joseph's Hospital</li></ul>","Phase":"I","Physician":"El-Rayes, Bassel","TrialName":"STA9090: Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer"},{"ClinicalTrialID":161,"NCTID":"NCT01567462","ProtocolNo":"WCI2119-11","CancerType":"Bladder","Drug":"","Location":"<ul><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"IV","Physician":"Ogan, Kenneth","TrialName":"PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors"},{"ClinicalTrialID":162,"NCTID":"NCT01638936","ProtocolNo":"BT983","CancerType":"Hematologic Cancers, Multiple Myeloma","Drug":"Dexamethasone, lenalidomide, Revlimid, BT062, Pomalidomide","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Heffner, L. Thompson","TrialName":"BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma"},{"ClinicalTrialID":163,"NCTID":"NCT01546038","ProtocolNo":"B1371003","CancerType":"Hematologic Cancers, Leukemias","Drug":"decitabine, Cytarabine, Dacogen, Daunorubicin, LDAC, PF-04449913","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Arellano, Martha","TrialName":"A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome"},{"ClinicalTrialID":164,"NCTID":"NCT02137759","ProtocolNo":"WINSHIP2434-13","CancerType":"Brain and Nervous System","Drug":"Temozolomide, Temodal, Vorinostat, SAHA","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Shu, Hui-Kuo","TrialName":"MRSI to Predict Response to RT/TMZ ± Vorinostat in GBM"},{"ClinicalTrialID":165,"NCTID":"NCT02269670","ProtocolNo":"WINSHIP2563-13","CancerType":"Breast - Female","Drug":"Anastrozole, Everolimus, fulvestrant, letrozole, megestrol acetate, tamoxifen, Arimadex, RAD001, Faslodex, Femara, Megace, Nolvadex","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li><li>Georgia Cancer Center for Excellence at Grady</li></ul>","Phase":"II","Physician":"Zelnak, Amelia","TrialName":"Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy"},{"ClinicalTrialID":166,"NCTID":"NCT02334319","ProtocolNo":"WINSHIP2572-13","CancerType":"Esophagus, Larynx, Lip, Oral Cavity and Pharynx","Drug":"STA-9090, Ganetespib","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"Pilot","Physician":"Saba, Nabil","TrialName":"Ganetespib Window of Opportunity Study in Head and Neck Cancers"},{"ClinicalTrialID":167,"NCTID":"NCT01466179","ProtocolNo":"MT103-211","CancerType":"Hematologic Cancers, Leukemias","Drug":"Blinatumomab","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Heffner, L. Thompson","TrialName":"Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)"},{"ClinicalTrialID":168,"NCTID":"NCT01718899","ProtocolNo":"2010-001","CancerType":"Hematologic Cancers, Multiple Myeloma","Drug":"PVX-410","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Nooka, Ajay","TrialName":"Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma"},{"ClinicalTrialID":169,"NCTID":"NCT01687244","ProtocolNo":"RAD-IFN-CS-002","CancerType":"Bladder","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Ogan, Kenneth","TrialName":"Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer"},{"ClinicalTrialID":170,"NCTID":"NCT01728805","ProtocolNo":"0761-010","CancerType":"Hematologic Cancers, Lymphomas","Drug":"Vorinostat, SAHA, KW-0761","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Lechowicz, Mary Jo","TrialName":"Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL"},{"ClinicalTrialID":171,"NCTID":"NCT01872975","ProtocolNo":"RTOG1304","CancerType":"Breast - Male, Breast Cancer, Solid Tumor Malignancies","Drug":"","Location":"<ul><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship at Emory University Hospital Midtown</li><li>Winship at Emory Saint Joseph's Hospital</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"III","Physician":"Torres, Mylin","TrialName":"Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery"},{"ClinicalTrialID":172,"NCTID":"NCT01856192","ProtocolNo":"E1412","CancerType":"Hematologic Cancers, Lymphomas","Drug":"cyclophosphamide, Doxorubicin, lenalidomide, Rituximab, vincristine, Cytoxan, Adriamycin, Revlimid, Rituxan, Oncovin, Doxorubicin Hydrochloride","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Cohen, Jonathon","TrialName":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma"},{"ClinicalTrialID":173,"NCTID":"NCT01550185","ProtocolNo":"I206111","CancerType":"Myeloid and Monocytic Leukemia","Drug":"Eltrombopag olamine, Promacta, SB-497115, SB 497115, SB497115","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Khoury, H. Jean","TrialName":"Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia"},{"ClinicalTrialID":174,"NCTID":"NCT01961115","ProtocolNo":"CITN-04","CancerType":"Melanoma, Solid Tumor Malignancies","Drug":"","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"II","Physician":"Lawson, David","TrialName":"INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma"},{"ClinicalTrialID":175,"NCTID":"NCT01480050","ProtocolNo":"ABTC1101","CancerType":"Brain Tumors/Neurologic Cancers, Solid Tumor Malignancies","Drug":"Temozolomide, Temodal, Mibefradil dihydrochloride","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"I","Physician":"Olson, Jeffrey","TrialName":"Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma"},{"ClinicalTrialID":176,"NCTID":"NCT01633060","ProtocolNo":"CBKM120F2303","CancerType":"Breast - Female, Solid Tumor Malignancies","Drug":"fulvestrant, Placebo, Faslodex, BKM120","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"III","Physician":"O'Regan, Ruth","TrialName":"A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi"},{"ClinicalTrialID":177,"NCTID":"NCT01691248","ProtocolNo":"OPT-80-302","CancerType":"Hematologic Cancers","Drug":"Placebo, Fidaxomicin","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Nooka, Ajay","TrialName":"Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation"},{"ClinicalTrialID":178,"NCTID":"NCT01582672","ProtocolNo":"AGS-003-007","CancerType":"Kidney","Drug":"sunitinib, AGS-003","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Master, Viraj","TrialName":"Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)"},{"ClinicalTrialID":179,"NCTID":"NCT01509911","ProtocolNo":"TLH-206","CancerType":"Gastrointestinal Cancers, Pancreas, Solid Tumor Malignancies","Drug":"Gemcitabine, Gemzar, TL-118","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"El-Rayes, Bassel","TrialName":"A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment"},{"ClinicalTrialID":180,"NCTID":"NCT01905657","ProtocolNo":"MK-3475-010-00","CancerType":"Lung Cancers, Non-small Cell Lung, Solid Tumor Malignancies","Drug":"docetaxel, Taxotere, MK-3475","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Ramalingam, Suresh","TrialName":"Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)"},{"ClinicalTrialID":181,"NCTID":"NCT01855750","ProtocolNo":"PCI-32765DBL3001","CancerType":"Hematologic Cancers, Lymphomas","Drug":"cyclophosphamide, Doxorubicin, prednisone, Rituximab, vincristine, Cytoxan, Adriamycin, Rituxan, Oncovin, Ibrutinib","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Flowers, Christopher","TrialName":"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma"},{"ClinicalTrialID":182,"NCTID":"NCT01873495","ProtocolNo":"WINSHIP2176-11","CancerType":"Leukemia, not otherwise specified, Leukemia, other","Drug":"ARA-C, Omacetaxine","Location":"Winship Cancer Institute of Emory University","Phase":"Pilot","Physician":"Arellano, Martha","TrialName":"Omacetaxine for Consolidation and Maintenance"},{"ClinicalTrialID":183,"NCTID":"NCT01711697","ProtocolNo":"RAD2179-12","CancerType":"Lung Cancers, Solid Tumor Malignancies","Drug":"carboplatin, paclitaxel, Paraplatin, Taxol","Location":"<ul><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"I","Physician":"Higgins, Kristin","TrialName":"Standard Radiation Therapy Combined With High Dose, Ablative Radiation in Patients With Advanced Lung Cancer That Cannot be Removed by Surgery"},{"ClinicalTrialID":184,"NCTID":"NCT01416428","ProtocolNo":"2011-001/ONX0912","CancerType":"Clinical Trials for Multiple Types of Cancer, Hematologic Cancers, Lymphomas, Mantle Cell Lymphoma, Multiple Myeloma, Phase 1 Clinical Trials, Waldenstrom's Macroglobulinemia","Drug":"ONX 0912","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Kaufman, Jonathan","TrialName":"Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies"},{"ClinicalTrialID":185,"NCTID":"NCT01642251","ProtocolNo":"E2511","CancerType":"Lung Cancers, Small Cell Lung, Solid Tumor Malignancies","Drug":"Cisplatin, Etoposide, Placebo, CDDP, VP-16, Cis-Platinum, etoposide phosphate, Veliparib","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"II","Physician":"Owonikoko, Taofeek","TrialName":"Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer"},{"ClinicalTrialID":186,"NCTID":"NCT01672736","ProtocolNo":"PPMHOSI906-MM001","CancerType":"Multiple Myeloma","Drug":"Bortezomib, Dexamethasone, Velcade, PS-341, OSI-906","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Kaufman, Jonathan","TrialName":"A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma"},{"ClinicalTrialID":187,"NCTID":"NCT01259856","ProtocolNo":"MPD-RC112","CancerType":"Hematologic Cancers, Leukemias","Drug":"Aspirin, Hydroxyurea, Hydrea, Pegasys","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Winton, Elliott","TrialName":"Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)"},{"ClinicalTrialID":188,"NCTID":"NCT00981656","ProtocolNo":"RTOG0926","CancerType":"Bladder","Drug":"5-fluorouracil, Cisplatin, mitomycin c, 5-FU, CDDP, Adrucil, Cis-Platinum","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Rossi, Peter","TrialName":"Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer"},{"ClinicalTrialID":189,"NCTID":"NCT01523171","ProtocolNo":"ARD12181","CancerType":"Hematologic Cancers, Leukemias, Myelofibrosis","Drug":"SAR302503","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Winton, Elliott","TrialName":"Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib"},{"ClinicalTrialID":190,"NCTID":"NCT01789242","ProtocolNo":"11-MM-02","CancerType":"Hematologic Cancers, Multiple Myeloma","Drug":"Dexamethasone, Carfilzomib","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Kaufman, Jonathan","TrialName":"A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis"},{"ClinicalTrialID":191,"NCTID":"NCT01850524","ProtocolNo":"C16014","CancerType":"Multiple Myeloma","Drug":"Dexamethasone, lenalidomide, Placebo, Revlimid","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Lonial, Sagar","TrialName":"IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma"},{"ClinicalTrialID":192,"NCTID":"NCT01259817","ProtocolNo":"MPD-RC111","CancerType":"Hematologic Cancers, Leukemias","Drug":"Aspirin, Pegasys","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Winton, Elliott","TrialName":"Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)"},{"ClinicalTrialID":193,"NCTID":"NCT01439347","ProtocolNo":"TTX404","CancerType":"Hematologic Cancers, Leukemias","Drug":"vincristine, Oncovin, Marquibo","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Heffner, L. Thompson","TrialName":"A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL"},{"ClinicalTrialID":194,"NCTID":"NCT01515787","ProtocolNo":"N1048","CancerType":"Gastrointestinal Cancers, Rectum, Solid Tumor Malignancies","Drug":"5-fluorouracil, capecitabine, oxaliplatin, 5-FU, Leucovorin, Xeloda, Adrucil","Location":"<ul><li>Winship at Emory University Hospital Midtown</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"III","Physician":"Sullivan, Patrick","TrialName":"Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery"},{"ClinicalTrialID":195,"NCTID":"NCT02234037","ProtocolNo":"WINSHIP2381-12","CancerType":"Hematologic Cancers, Leukemias","Drug":"decitabine, Dacogen","Location":"Winship Cancer Institute of Emory University","Phase":"Pilot","Physician":"Arellano, Martha","TrialName":"Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age > 60"},{"ClinicalTrialID":196,"NCTID":"NCT01862328","ProtocolNo":"C15010","CancerType":"Adrenocortical, Anus, Bladder, Bones and Joints, Brain Tumors/Neurologic Cancers, Breast - Female, Breast - Male, Breast Cancer, Cervix, Clinical Trials for Multiple Types of Cancer, Colon, Colorectal, Endocrine Cancers, Esophagus, Eye and Orbit, Fallopian Tube, GVHD (Graft vs. Host Disease), Gastrointestinal Cancers, Glioblastoma Multiforme, Glioma, Gynecologic Cancers, Head and Neck Cancers, Kidney (Renal), Liver, Lung Cancers, Male Cancers, Meningioma, Mesothelioma, Metastases, Neuroendocrine, Ovary, Pancreas, Penis, Peritoneum, Phase 1 Clinical Trials, Prostate, Rectum, Sarcomas, Solid Tumor Malignancies, Stomach, Supportive Care Trials, Testes, Thyroid, Urologic/Genitourinary Cancers, Uterus, Vagina/Vulva","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Harvey, R. Donald","TrialName":"Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors"},{"ClinicalTrialID":197,"NCTID":"NCT01877655","ProtocolNo":"0113-CL-1004","CancerType":"Hematologic Cancers, Leukemias, Lymphomas, Mantle Cell Lymphoma","Drug":"ASP0113","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Langston, Amelia","TrialName":"A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)"},{"ClinicalTrialID":198,"NCTID":"NCT01169337","ProtocolNo":"E3A06","CancerType":"Hematologic Cancers, Multiple Myeloma","Drug":"lenalidomide, Revlimid","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Lonial, Sagar","TrialName":"Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma"},{"ClinicalTrialID":199,"NCTID":"NCT01272037","ProtocolNo":"S1007","CancerType":"Breast - Female, Breast - Male, Breast Cancer, Solid Tumor Malignancies","Drug":"Anastrozole, exemestane, letrozole, tamoxifen, Arimadex, Aromasin, Femara, Nolvadex","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship at Emory University Hospital Midtown</li><li>Winship at Emory Saint Joseph's Hospital</li></ul>","Phase":"III","Physician":"O'Regan, Ruth","TrialName":"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer"},{"ClinicalTrialID":200,"NCTID":"NCT01627314","ProtocolNo":"FT1050-03","CancerType":"Hodgkin's Lymphoma, Leukemia, not otherwise specified, Leukemia, other, Lymphoid Leukemia, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other Hematopoietic","Drug":"cyclophosphamide, cyclosporine, fludarabine, Melphalan, mycophenolate mofetil, prograf, sirolimus, tacrolimus, Cytoxan, Fludara, Alkeran, Cellcept, Rapamune, G-CSF, fludarabine phosphate, L-PAM, Total Body Irradiation, Rabbit ATG, Untreated CB, Cord Blood, ProHema-CB","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Waller, Edmund","TrialName":"The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies."},{"ClinicalTrialID":201,"NCTID":"NCT01593748","ProtocolNo":"MUSC-101644","CancerType":"Soft Tissue","Drug":"docetaxel, Gemcitabine, pazopanib, Taxotere, Gemzar, GW786034","Location":"<ul><li>Winship Cancer Institute of Emory University</li><li>Winship at Emory University Hospital Midtown</li></ul>","Phase":"II","Physician":"Read, William","TrialName":"A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma"},{"ClinicalTrialID":202,"NCTID":"NCT01808573","ProtocolNo":"PUMA-NER-1301","CancerType":"Breast - Female, Breast - Male, Solid Tumor Malignancies","Drug":"capecitabine, lapatinib, Xeloda, Neratinib","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Zelnak, Amelia","TrialName":"A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting"},{"ClinicalTrialID":203,"NCTID":"NCT01231412","ProtocolNo":"FHCRC2448","CancerType":"GVHD (Graft vs. Host Disease), Hematologic Cancers, Leukemias, Lymphomas, Multiple Myeloma","Drug":"cyclosporine, mycophenolate mofetil, sirolimus, Cellcept, Rapamune","Location":"<ul><li>Georgia Cancer Center for Excellence at Grady</li><li>Winship Cancer Institute of Emory University</li></ul>","Phase":"II","Physician":"Langston, Amelia","TrialName":"Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant"},{"ClinicalTrialID":204,"NCTID":"NCT01395407","ProtocolNo":"RADONC1962-11","CancerType":"Brain and Nervous System, Lung","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Crocker, Ian","TrialName":"Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases"},{"ClinicalTrialID":205,"NCTID":"NCT01146834","ProtocolNo":"1005011049","CancerType":"Hematologic Cancers, Multiple Myeloma","Drug":"cyclophosphamide, Velcade, Cytoxan, G-CSF","Location":"Winship Cancer Institute of Emory University","Phase":"III","Physician":"Kaufman, Jonathan","TrialName":"Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma"},{"ClinicalTrialID":206,"NCTID":"NCT01926678","ProtocolNo":"R21AT007090-01A1","CancerType":"Breast - Female","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Rapaport, Mark","TrialName":"Efficacy of Swedish Massage Therapy on Cancer-related Fatigue in Cancer Survivors"},{"ClinicalTrialID":207,"NCTID":"NCT01830816","ProtocolNo":"C16015","CancerType":"Any Site","Drug":"","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Lonial, Sagar","TrialName":"Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment"},{"ClinicalTrialID":208,"NCTID":"NCT01543776","ProtocolNo":"UCCCC11-0709","CancerType":"Phase 1 Clinical Trials, Prostate, Solid Tumor Malignancies","Drug":"Abiraterone","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Carthon, Bradley","TrialName":"Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer"},{"ClinicalTrialID":209,"NCTID":"NCT01323751","ProtocolNo":"ACY-100","CancerType":"Hematologic Cancers, Multiple Myeloma, Phase 1 Clinical Trials","Drug":"Bortezomib, Dexamethasone, Velcade, PS-341, ACY-1215","Location":"Winship Cancer Institute of Emory University","Phase":"I","Physician":"Lonial, Sagar","TrialName":"Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma"},{"ClinicalTrialID":210,"NCTID":"NCT01216683","ProtocolNo":"E2408","CancerType":"Hematologic Cancers, Lymphomas","Drug":"Bortezomib, lenalidomide, Rituximab, Velcade, Revlimid, Rituxan, PS-341, bendamustine","Location":"Winship Cancer Institute of Emory University","Phase":"II","Physician":"Flowers, Christopher","TrialName":"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma"}]